Candriam S.C.A. Relay Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $16.9 Billion
- Q4 2024
A detailed history of Candriam S.C.A. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 1,729,199 shares of RLAY stock, worth $6.92 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,729,199
Previous 1,092,705
58.25%
Holding current value
$6.92 Million
Previous $7.74 Million
7.91%
% of portfolio
0.04%
Previous 0.05%
Shares
13 transactions
Others Institutions Holding RLAY
# of Institutions
208Shares Held
162MCall Options Held
102KPut Options Held
28.8K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$112 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15MShares$60.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$42.2 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY8.95MShares$35.8 Million3.17% of portfolio
-
Tang Capital Management LLC San Diego, CA8.07MShares$32.3 Million2.5% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $481M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...